SHUKRA
PHARMACEUTICALS LTD.

29th May, 2023

To,
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Fort
Mumbai - 400001

Scrip Code: 524632

Dear Sir/Madam,

uiremen

Pursuant to Regulation 32 of SEBI (listing Obligations and Disclosure Requirements) Regulation, 2015 we hereby confirm that there is no deviation and/or variation in the utilization of proceeds, from the object mentioned in the letter of offer dated February 01, 2023 for Right Issue of 93,94,050 partly paid-up equity shares in which Rs. 5/- each was payable on application. It is further confirmed that the proceeds of 93,94,050 Partly Paid-up equity shares on a Right basis on during the Quarter and year ended 31st March, 2023, have been fully utilized.

A statement of deviation, stating that there is no deviation or variation in the utilization of these proceeds, duly reviewed by the Audit Committee, is attached herewith as **Annexure-A**.

This is for your kind information and record.

Thanking You

Yours faithfully

kra Pharmaceuticals Limited

DIN:0836893

Encl.: a/a

CIN : L24231GJ1993PLC019079

Regd. Office : 3rd Floor, "VEER HOUSE" Opp. WIAA Office, Judges Bunglow Road, Bodakdev, Ahmedabad-380 054.
Factory Add. : 795, Rakanpur, Sola-Santej Road, Ta. Kalol, Dist. Gandhinagar-382721, Gujarat, India, Ph. : 02764-286317

SHUKRA

Statement of Deviation / Variation in utilization of funds raised under Right issue - Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Name of Listed Entity	Shukra Pharmaceuticals Limited
Mode of Fund Raising	Right Issue of Partly Paid-Up Equity Shares
Date of Raising Fund	March 09, 2023
Amount Raised	Rs. 4.69 Crores (25% received on application) (Total amount raised under Rights issue is Rs. 18.78 Crores)
Report filed for Quarter and Year Ended	March 31, 2023
Monitoring Agency	NA
Monitoring Agency Name, If Applicable	NA
Is there any Deviation / Variation in use of funds raised	No
If yes, Whether the same is pursuant to change in terms of a contract or object, which was approved by the shareholders	NA
If Yes, Date of Shareholder approval	NA
Explanation for Deviation / Variation	NA
Comments of Audit Committee after review	No Comments
Comments of auditors. if any	No Comments

SHUKRA PHARMACEUTICALS LTD. AHMEDABAD

SHUKRA
PHARMACEUTICALS LTD.

Original Object	Modified Object, if any	*Original Allocation	Modified allocation, if any	Funds Utilized	Amount of Deviation/ Variation for the quarter according to applicable object	Remarks if any
Existing and incremental working capital requirement of our company	Nil	Rs. 13.54 Crores	Nil	Rs. 3.52 Crores	Nil	No deviation
General Corporate Purposes	Nil	Rs. 4.69 Crores	Nil	Rs. 1.17 Crores	Nil	No deviation

**The company has received 25% amount on application of the total allocation amount and remaining amount shall be payable on the calls as determined by the board.*

(a) Deviation in the objects or purposes for which the funds have been raised; or
(b) Deviation in the amount of funds actually utilized as against what was originally disclosed; or
(c) Change in terms of a contract referred to in the fundraising document i.e. prospectus, letter of offer, etc

Pharmaceuticals Limited

Director
DIN:0836893